The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
-
Sylvester Comprehensive Cancer Center, Miami, Florida, United States, 33136-1002
Florida Cancer Specialists, Sarasota, Florida, United States, 34232-6422
The Emory Clinic, Atlanta, Georgia, United States, 30322-1013
Northwestern University, Chicago, Illinois, United States, 60611-3013
Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 02215
Mayo Clinic- Minnesota, Rochester, Minnesota, United States, 55905
University Of Nebraska Medical Center, Omaha, Nebraska, United States, 69198
Cayuga Cancer Center, Ithaca, New York, United States, 14850
Northwell Health, Lake Success, New York, United States, 11042-1118
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York, New York, United States, 10065-6007
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Eli Lilly and Company,
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), STUDY_DIRECTOR, Eli Lilly and Company
2032-12